Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Marco Montillo, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Eleonora Vismara, MD, Denis Ciapanna, MD, Valeria Belsito Petrizzi, MD, Monica Crugnola, MD, Mauro Spriano, MD, Lilj Uziel, MD, Angelo De Blasio, MD, Pierangelo Spedini, PhD, Enrica Morra, MD

Blood (2007) 110 (11): 3133.

https://doi.org/10.1182/blood.V110.11.3133.3133

Published: 2007

Journal Articles

Intermediate Dose Ara-C Followed by G-CSF: An Effective and Predictable Mobilization Regimen in Hematological Malignancies.

Francesca Ricci, MD, Marco Montillo, MD, Alessandra Tedeschi, MD, Sara Miqueleiz, MD, Erika Ravelli, MD, Liliana Intropido, PhD, Barbara Scarapati, PhD, Enrica Morra, MD

Blood (2007) 110 (11): 3290.

https://doi.org/10.1182/blood.V110.11.3290.3290

Published: 2007

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results

Alessandra Tedeschi, MD, Sara Miqueleiz, MD, Francesca Ricci, MD, Annalisa Luraschi, MD, Mario Schiavone, MD, Alessandro Andriani, MD, Maria Teresa Petrucci, MD, Felicetto Ferrara, MD, Enrica Morra, MD

Blood (2007) 110 (11): 1290.

https://doi.org/10.1182/blood.V110.11.1290.1290

Published: 2007

Journal Articles

Transient Massive Lymphoid Bone Marrow Infiltrate Developing during Therapy with the Tyrosine Kinase Inhibitors Imatinib and Nilotinib: Report of 2 Patients.

Ester Pungolino, MD, Silvia Cantoni, MD, Cecilia Del Curto, MD, Livio Gargantini, MD, Marianna Caramella, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Michela Draisci, MD, Cristina Gabutti, MD, Simona Paratore, MD, Karen Lanza, BD, Sonia Ribera, MD, Enrica Morra, MD

Blood (2007) 110 (11): 4577.

https://doi.org/10.1182/blood.V110.11.4577.4577

Published: 2007

Journal Articles

Oxaliplatin as Single Agent or in Combination in Chronic Lymphocytic Leukaemia (CLL).

Marco Montillo, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Alfredo Molteni, MD, Enrica Morra, MD

Blood (2006) 108 (11): 4982.

https://doi.org/10.1182/blood.V108.11.4982.4982

Published: 2006

NARROW

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Intermediate Dose Ara-C Followed by G-CSF: An Effective and Predictable Mobilization Regimen in Hematological Malignancies.

Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results

Transient Massive Lymphoid Bone Marrow Infiltrate Developing during Therapy with the Tyrosine Kinase Inhibitors Imatinib and Nilotinib: Report of 2 Patients.

Oxaliplatin as Single Agent or in Combination in Chronic Lymphocytic Leukaemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Intermediate Dose Ara-C Followed by G-CSF: An Effective and Predictable Mobilization Regimen in Hematological Malignancies.

Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results

Transient Massive Lymphoid Bone Marrow Infiltrate Developing during Therapy with the Tyrosine Kinase Inhibitors Imatinib and Nilotinib: Report of 2 Patients.

Oxaliplatin as Single Agent or in Combination in Chronic Lymphocytic Leukaemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only